Because the World Well being Group just lately issued steerage supporting using GLP-1 drugs in weight problems care, these medicine reached a brand new milestone. For sufferers, it marks a much-needed shift away from willpower-based narratives and towards understanding weight as one thing rooted in biology.
However lengthy earlier than Ozempic and Wegovy turned family names, the story of GLP-1s began with early gut-hormone analysis—and an unlikely breakthrough courtesy of a venomous desert lizard. Under, consultants stroll us by way of the science of GLP-1s: the place it started, what we’ve realized and the place the sector is headed subsequent.
Featured Consultants
- Amanda Kahn, MD is a board-certified internist and longevity professional in New York
- Andrea Traina, Pharm D, is an weight problems director at Novo Nordisk
- Eduardo Grunvald, MD is a board-certified internist and weight problems drugs specialist in San Diego, CA
The Intestine Hormone That Nearly Didn’t Make It
Within the Nineteen Eighties and Nineteen Nineties, researchers had been attempting to grasp how the physique regulates blood sugar after meals. That work led to the invention of glucagon-like peptide-1 (GLP-1), a hormone launched from the small gut that helps management insulin secretion, sluggish digestion and cut back urge for food. “Early researchers observed that GLP-1 powerfully and appropriately stimulated insulin solely when glucose ranges had been excessive, which means it lowered blood sugar with out inflicting harmful hypoglycemia,” says New York internist and longevity professional Amanda Kahn, MD. “It additionally slowed gastric emptying and decreased urge for food, which instantly made it totally different from different diabetes hormones.”
The issue was timing: pure GLP-1 is damaged down inside minutes, making it impractical as a medicine. For some time, it appeared like promising biology with no path ahead.
Enter the Gila Monster
Then the reply arrived from an surprising place: the Gila monster, a venomous desert lizard recognized for consuming sometimes and surviving lengthy intervals with out meals. “The saliva of the Gila monster creates a substance that appears similar to the GLP-1 our physique naturally makes,” explains Andrea Traina, PharmD, weight problems medical director for Novo Nordisk. “What the Gila monster makes is Exendin 4. This turned the premise for exenatide, the primary GLP-1 receptor agonist medicine permitted in 2005. It was short-acting, lasted a number of hours and was dosed twice a day earlier than meals. That little lizard utterly revolutionized our understanding of urge for food management, and glucose metabolism,” says Traina. “The scientific neighborhood has realized a lot from it.”
What made Exendin 4 totally different was sturdiness. It resisted speedy breakdown, giving scientists a blueprint for designing longer-acting medicine. “That little lizard utterly revolutionized our understanding of urge for food management, glucose metabolism and irritation,” says Traina. “We’ve realized a lot from it.”
From Diabetes Drug to Weight-Loss Device
When exenatide reached diabetes clinics, docs observed one thing surprising. Sufferers not solely improved their blood sugar ranges but additionally misplaced significant weight. “Clinicians started noticing vital weight reduction in diabetes sufferers taking early GLP-1 medicine like exenatide and liraglutide within the mid-2000s,” says Dr. Kahn. “The turning level got here round 2015, when higher-dose liraglutide, beneath the model identify Saxenda, was permitted for weight problems, confirming the load loss impact wasn’t only a aspect impact, however a main therapeutic motion.”
GLP-1s labored in another way from earlier food plan medicine. “The rationale many individuals wrestle to drop some pounds with way of life adjustments alone is that the biology will get in the way in which,” says San Diego internist and weight problems specialist Eduardo Grunvald, MD. “These drugs cut back starvation, cravings and the reward response to high-fat, high-sugar meals, serving to folks really feel full with much less meals.” For a lot of sufferers, that shift exhibits up as quiet. Fewer cravings. Much less meals noise.
Semaglutide, the lively ingredient in Wegovy and Ozempic, pushed the category additional. Giant trials confirmed advantages that prolonged past weight alone. “We’ve a medicine that’s well-known, revered and confirmed secure and efficient past the dimensions,” notes Traina. “Not simply weight discount, however reductions in coronary heart assault, stroke and cardiovascular loss of life.” These findings helped reposition GLP-1s as long-term metabolic therapies quite than short-term fixes.
The place the Science Is Headed Now
The subsequent section of the GLP-1 story is much less about format and extra about stability within the physique over time, a shift that turned tangible in December 2025 when the FDA permitted Novo Nordisk’s oral semaglutide (Wegovy), the primary every day GLP-1 tablet cleared for weight problems remedy. What was as soon as investigational is now actuality. As scientists realized how you can make these drugs last more in our programs, the main focus shifted as to if that very same consistency may prolong past injections. “We now have a medicine that’s confirmed for security and efficacy past the dimensions accessible in a every day tablet with an identical security and efficacy profile to the once-weekly injection,” says Traina. “That’s actually first of its form.”
Getting there took a long time. “GLP-1s are peptide-based molecules that aren’t designed to be absorbed orally,” Traina explains. “It took years of analysis to develop a formulation that quickly adjustments the abdomen atmosphere, protects the drug from being damaged down and permits sufficient semaglutide to be absorbed to have a therapeutic impact.”
The Capsule Period Begins
In late-stage trials, sufferers taking the best oral dose of Wegovy misplaced about 14 % of their physique weight, outcomes akin to the injectable model. Like its once-weekly counterpart, the tablet can also be permitted to scale back cardiovascular threat, reinforcing the concept that GLP-1 drugs at the moment are seen as long-term metabolic therapies quite than short-term weight-loss instruments.
The pill have to be taken on an empty abdomen, with a 30-minute window earlier than consuming, reflecting the precision required to permit absorption within the digestive tract. Nonetheless, the approval marks a significant enlargement in entry. Weekly injections stay foundational, however every day oral remedy provides one other entry level into care, notably for sufferers hesitant about needles or looking for a remedy that matches extra seamlessly right into a morning routine.
What the Lizard Began
Whereas the story begins with a lizard, its influence reaches a lot additional. “GLP-1 confirmed us that the intestine has been performing like an endocrine organ all alongside,” says Dr. Kahn. “By being attentive to it, we uncovered probably the most highly effective instruments for metabolic well being and longevity that drugs has recognized.”
For many individuals on GLP-1s, the expertise has been quietly validating—confirming that what they had been lacking wasn’t willpower however the organic swap that silences meals noise, a discovery that traces all the way in which again to the Gila monster.
